<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724592</url>
  </required_header>
  <id_info>
    <org_study_id>BB001/13</org_study_id>
    <nct_id>NCT02724592</nct_id>
  </id_info>
  <brief_title>Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions</brief_title>
  <official_title>Effect of Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions: A Mono-centre, Controlled, Single-blinded, Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: Occlusal surfaces of erupting permanent molars are highly prone to caries.&#xD;
      Self-assembling peptide (P11-4) has proven to enhance biomimetic mineralization of early&#xD;
      carious lesions. Aim of this study was to evaluate safety, clinical applicability and effect&#xD;
      of using P11-4 (Curodont™ Repair) in non-invasive treatment of early occlusal lesions.&#xD;
&#xD;
      Methods: 70 patients with active early occlusal lesions (ICDAS-II:1-3) on first or second&#xD;
      permanent molars at eruption will be allocated in this randomized, controlled, single blinded&#xD;
      study to test (Curodont™ Repair+Duraphat®) or control (Duraphat®) groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: Occlusal surfaces of erupting permanent molars are high prone to caries.&#xD;
      Self-assembling peptide (P11-4) has proven to enhance biomimetic mineralization of early&#xD;
      carious lesions. Aim of this study was to evaluate safety, clinical applicability and effect&#xD;
      of using P11-4 (Curodont™ Repair) in non-invasive treatment of early occlusal lesions.&#xD;
&#xD;
      Methods: 70 patients with active early occlusal lesions (ICDAS-II:1-3) on first or second&#xD;
      permanent molars at eruption will be allocated in this randomized, controlled, single blinded&#xD;
      study to test (Curodont™ Repair+Duraphat®) or control (Duraphat®) groups. Safety and&#xD;
      applicability will be evaluated using dentist's/patient's questionnaires about adverse&#xD;
      events, difficulties of application and satisfaction with procedure. Lesions will be assessed&#xD;
      at baseline and recalls after 3 and 6 months regarding caries activity, clinical status&#xD;
      (ICDAS-II) and with Diagnodent®. The Visual Analog Scale (VAS) of regression and of lesion&#xD;
      size in addition to the Global Impression of Change Questionnaire will also be assessed. At&#xD;
      every recall, fluoride varnish will be applied on lesions and patients received oral health&#xD;
      instructions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Caries Activity and Progression Assessment Using LASER Fluorescence Readings by Diagnodent® Device.</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of the additional therapeutic benefit of Curodont™ compared to fluoride varnish (Duraphat®) alone on early occlusal carious lesions using LASER &quot;Light Amplification by Stimulated Emission of Radiation&quot; fluorescence readings by Diagnodent® device.&#xD;
Diagnodent® device measures the caries activity using LASER fluorescence of bacterial secretions in the caries lesion. The readings range from 0 to 99; 0 means no bacterial activity in the carious lesion whereas 99 refers to high bacterial and caries activity.&#xD;
Effect via the changes in LASER fluorescence readings between Baseline and 6-months recall (Change = Baseline value - 6 months value). Higher positive change value means caries regression, whereas lower positive or negative change value refers to caries progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale of Lesion Progression (VAS)</measure>
    <time_frame>6 months</time_frame>
    <description>Visual Analog Scale of lesion progression (VAS), Effect via t test between Baseline and 6-months recall VAS values range from -100 % to +100 %. The value of -100 means that the carious lesion is strongly remineralising, the value of 0 means that the lesion is arrested, and the value of +100 means that the lesion is strongly progressing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICDAS Classification Index</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients who have improvement on the ICDAS classification index (International Caries Detection and Assessment System), changes from Baseline to 6-months recall.&#xD;
This carries clinical index range from 0 to 6. The values mean:&#xD;
0 No evidence of caries&#xD;
Initial caries&#xD;
Distinct visual change in enamel&#xD;
Localised enamel breakdown due to caries with no visible dentine&#xD;
Underlying dark shadow from dentine&#xD;
Distinct cavity with visible dentine&#xD;
Extensive distinct cavity with visible dentine. During the study, a change from level to lower level number (e.g. from 2 to 1) in patients means that the carious lesion is regressed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caries Activity Assessment According to Nyvad Criteria</measure>
    <time_frame>6 months</time_frame>
    <description>Caries activity assessment according to Nyvad criteria, number of participants still have active lesions overall study.&#xD;
This assessment includes two clinical judgment inserts: active lesion or inactive lesion basing on visual-tactile surface characteristics of the caries lesions such as integrity, texture, translucency/opacity, lesion location, and surface color.&#xD;
During the study, an alteration from active lesion to in active lesion means an improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Dental Caries</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group, only Fluoride varnish (Duraphat®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>self assembling peptide P11-4 (Curodont™ Repair)</intervention_name>
    <description>Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions</description>
    <arm_group_label>intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>fluoride varnish (Duraphat®)</intervention_name>
    <description>Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Early occlusal carious lesions (without cavity) on permanent molar &quot;6&quot; or &quot;7&quot; at&#xD;
             eruption which does not require an invasive treatment&#xD;
&#xD;
          -  Age ≥ 5 years&#xD;
&#xD;
          -  Size and form of the lesions: the lesions must both be fully visible and assessable&#xD;
             and accessible&#xD;
&#xD;
          -  Willing and able to attend the on-study visits and to observe good oral hygiene&#xD;
             throughout the study&#xD;
&#xD;
          -  Written informed consent before participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of tooth erosion&#xD;
&#xD;
          -  Fluoride varnish application &lt; 3 months prior to study treatment&#xD;
&#xD;
          -  History of head and neck illnesses (e.g. head/neck cancer)&#xD;
&#xD;
          -  Any pathology or concomitant medication affecting salivary flow or dry mouth&#xD;
&#xD;
          -  Any metabolic disorders affecting bone turnover&#xD;
&#xD;
          -  Concurrent participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad Alkilzy, Dr. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Greifswald</affiliation>
  </overall_official>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <results_first_submitted>February 27, 2017</results_first_submitted>
  <results_first_submitted_qc>March 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2021</results_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Fluorides, Topical</mesh_term>
    <mesh_term>Sodium fluoride topical preparation</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>70 patients met the inclusion criteria and offered participation</recruitment_details>
      <pre_assignment_details>No patient declined to participate</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)&#xD;
self assembling peptide P11-4 (Curodont™ Repair): Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>control group, only Fluoride varnish (Duraphat®)&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)&#xD;
self assembling peptide P11-4 (Curodont™ Repair): Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>control group, only Fluoride varnish (Duraphat®)&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.0" lower_limit="7.0" upper_limit="13.0"/>
                    <measurement group_id="B2" value="10.5" lower_limit="8.0" upper_limit="13.0"/>
                    <measurement group_id="B3" value="9.75" lower_limit="7.0" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Caries Activity and Progression Assessment Using LASER Fluorescence Readings by Diagnodent® Device.</title>
        <description>Evaluation of the additional therapeutic benefit of Curodont™ compared to fluoride varnish (Duraphat®) alone on early occlusal carious lesions using LASER &quot;Light Amplification by Stimulated Emission of Radiation&quot; fluorescence readings by Diagnodent® device.&#xD;
Diagnodent® device measures the caries activity using LASER fluorescence of bacterial secretions in the caries lesion. The readings range from 0 to 99; 0 means no bacterial activity in the carious lesion whereas 99 refers to high bacterial and caries activity.&#xD;
Effect via the changes in LASER fluorescence readings between Baseline and 6-months recall (Change = Baseline value - 6 months value). Higher positive change value means caries regression, whereas lower positive or negative change value refers to caries progression.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)&#xD;
self assembling peptide P11-4 (Curodont™ Repair): Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>control group, only Fluoride varnish (Duraphat®)&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Caries Activity and Progression Assessment Using LASER Fluorescence Readings by Diagnodent® Device.</title>
          <description>Evaluation of the additional therapeutic benefit of Curodont™ compared to fluoride varnish (Duraphat®) alone on early occlusal carious lesions using LASER &quot;Light Amplification by Stimulated Emission of Radiation&quot; fluorescence readings by Diagnodent® device.&#xD;
Diagnodent® device measures the caries activity using LASER fluorescence of bacterial secretions in the caries lesion. The readings range from 0 to 99; 0 means no bacterial activity in the carious lesion whereas 99 refers to high bacterial and caries activity.&#xD;
Effect via the changes in LASER fluorescence readings between Baseline and 6-months recall (Change = Baseline value - 6 months value). Higher positive change value means caries regression, whereas lower positive or negative change value refers to caries progression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" spread="19.8"/>
                    <measurement group_id="O2" value="1.1" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale of Lesion Progression (VAS)</title>
        <description>Visual Analog Scale of lesion progression (VAS), Effect via t test between Baseline and 6-months recall VAS values range from -100 % to +100 %. The value of -100 means that the carious lesion is strongly remineralising, the value of 0 means that the lesion is arrested, and the value of +100 means that the lesion is strongly progressing.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)&#xD;
self assembling peptide P11-4 (Curodont™ Repair): Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>control group, only Fluoride varnish (Duraphat®)&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale of Lesion Progression (VAS)</title>
          <description>Visual Analog Scale of lesion progression (VAS), Effect via t test between Baseline and 6-months recall VAS values range from -100 % to +100 %. The value of -100 means that the carious lesion is strongly remineralising, the value of 0 means that the lesion is arrested, and the value of +100 means that the lesion is strongly progressing.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" spread="40.8"/>
                    <measurement group_id="O2" value="49.1" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICDAS Classification Index</title>
        <description>Number of patients who have improvement on the ICDAS classification index (International Caries Detection and Assessment System), changes from Baseline to 6-months recall.&#xD;
This carries clinical index range from 0 to 6. The values mean:&#xD;
0 No evidence of caries&#xD;
Initial caries&#xD;
Distinct visual change in enamel&#xD;
Localised enamel breakdown due to caries with no visible dentine&#xD;
Underlying dark shadow from dentine&#xD;
Distinct cavity with visible dentine&#xD;
Extensive distinct cavity with visible dentine. During the study, a change from level to lower level number (e.g. from 2 to 1) in patients means that the carious lesion is regressed.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)&#xD;
self assembling peptide P11-4 (Curodont™ Repair): Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>control group, only Fluoride varnish (Duraphat®)&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
          </group>
        </group_list>
        <measure>
          <title>ICDAS Classification Index</title>
          <description>Number of patients who have improvement on the ICDAS classification index (International Caries Detection and Assessment System), changes from Baseline to 6-months recall.&#xD;
This carries clinical index range from 0 to 6. The values mean:&#xD;
0 No evidence of caries&#xD;
Initial caries&#xD;
Distinct visual change in enamel&#xD;
Localised enamel breakdown due to caries with no visible dentine&#xD;
Underlying dark shadow from dentine&#xD;
Distinct cavity with visible dentine&#xD;
Extensive distinct cavity with visible dentine. During the study, a change from level to lower level number (e.g. from 2 to 1) in patients means that the carious lesion is regressed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Caries Activity Assessment According to Nyvad Criteria</title>
        <description>Caries activity assessment according to Nyvad criteria, number of participants still have active lesions overall study.&#xD;
This assessment includes two clinical judgment inserts: active lesion or inactive lesion basing on visual-tactile surface characteristics of the caries lesions such as integrity, texture, translucency/opacity, lesion location, and surface color.&#xD;
During the study, an alteration from active lesion to in active lesion means an improvement.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)&#xD;
self assembling peptide P11-4 (Curodont™ Repair): Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>control group, only Fluoride varnish (Duraphat®)&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Caries Activity Assessment According to Nyvad Criteria</title>
          <description>Caries activity assessment according to Nyvad criteria, number of participants still have active lesions overall study.&#xD;
This assessment includes two clinical judgment inserts: active lesion or inactive lesion basing on visual-tactile surface characteristics of the caries lesions such as integrity, texture, translucency/opacity, lesion location, and surface color.&#xD;
During the study, an alteration from active lesion to in active lesion means an improvement.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Incidence of Treatment-Emergent Adverse Events (definitions are adapted from Directive 2001/20/EC and in accordance with ISO 14155 and MDD 93/42). Safety definitions are adapted from the Directive 2001/20/EC and in accordance with ISO 14155 and MDD 93/42.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)&#xD;
self assembling peptide P11-4 (Curodont™ Repair): Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>control group, only Fluoride varnish (Duraphat®)&#xD;
fluoride varnish (Duraphat®): Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mohammad Alkilzy</name_or_title>
      <organization>University of Greifswald</organization>
      <phone>0049-17623399340</phone>
      <email>alkilzym@uni-greifswald.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

